Gemcitabine intravesical sys
Products billed under this code include Inlexzo.
Payment limit per 225 MG, by effective quarter, 2Q26 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under J9183
From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Inlexzo | Janssen Biotech, Inc. | 57894-0225-01 | 1 | $73,054.053 |
Every quarter
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $73,054.053 | +$69.812 | 225 MG | Gemcitabine intravesical sys | v1, posted September 17, 2026 |
| 3Q26 | $72,984.241 | −$104.019 | 225 MG | Gemcitabine intravesical sys | v1, posted September 15, 2026 |
| 2Q26 | $73,088.26 | – | 225 MG | Gemcitabine intravesical sys | v1, posted September 15, 2026 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.
CMS source files
- 4Q26: 2026-09-17_october-2026-medicare-part-b-payment-limit-files-final.zipposted September 17, 2026
- 4Q26: 2026-09-17_october-2026-ndc-hcpcs-crosswalk-final.zipposted September 17, 2026
- 3Q26: 2026-09-15_july-2026-medicare-part-b-payment-limit-files.zipposted September 15, 2026
- 2Q26: 2026-09-15_april-2026-medicare-part-b-payment-limit-files-final-file.zipposted September 15, 2026